Eidelman Virant Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-3,675
| Closed | -$218K | – | 212 |
|
|
2021
Q4 | $218K | Buy |
+3,675
| New | +$182K | 0.08% | 170 |
|
|
2021
Q3 | – | Sell |
-6,175
| Closed | -$241K | – | 199 |
|
|
2021
Q2 | $241K | Sell |
6,175
-8,475
| -58% | -$330K | 0.09% | 147 |
|
|
2021
Q1 | $533K | Sell |
14,650
-1,200
| -8% | -$42.6K | 0.21% | 93 |
|
|
2020
Q4 | $583K | Sell |
15,850
-6,442
| -29% | -$236K | 0.25% | 79 |
|
|
2020
Q3 | $771K | Sell |
22,292
-843
| -4% | -$29.6K | 0.42% | 52 |
|
|
2020
Q2 | $718K | Hold |
23,135
| – | – | 0.5% | 44 |
|
|
2020
Q1 | $716K | Sell |
23,135
-64,347
| -74% | -$2.19M | 0.74% | 37 |
|
|
2019
Q4 | $3.25M | Buy |
87,482
+72,199
| +472% | +$2.57M | 1.59% | 15 |
|
|
2019
Q3 | $521K | Sell |
15,283
-3,689
| -19% | -$134K | 0.3% | 78 |
|
|
2019
Q2 | $779K | Sell |
18,972
-2,740
| -13% | -$109K | 0.41% | 59 |
|
|
2019
Q1 | $874K | Sell |
21,712
-844
| -4% | -$33.8K | 0.61% | 50 |
|
|
2018
Q4 | $934K | Sell |
22,556
-210
| -0.9% | -$8.72K | 0.7% | 50 |
|
|
2018
Q3 | $951K | Sell |
22,766
-106
| -0.5% | -$4.08K | 0.47% | 65 |
|
|
2018
Q2 | $787K | Sell |
22,872
-53
| -0.2% | -$1.81K | 0.49% | 55 |
|
|
2018
Q1 | $771K | Sell |
22,925
-107,697
| -82% | -$3.7M | 0.5% | 56 |
|
|
2017
Q4 | $4.49M | Sell |
130,622
-23,188
| -15% | -$791K | 2.63% | 9 |
|
|
2017
Q3 | $5.21M | Buy |
153,810
+130,169
| +551% | +$4.18M | 3.1% | 5 |
|
|
2017
Q2 | $753K | Sell |
23,641
-424
| -2% | -$13.4K | 0.43% | 66 |
|
|
2017
Q1 | $781K | Sell |
24,065
-6,851
| -22% | -$216K | 0.54% | 58 |
|
|
2016
Q4 | $952K | Buy |
30,916
+3,858
| +14% | +$118K | 0.54% | 52 |
|
|
2016
Q3 | $869K | Sell |
27,058
-25,064
| -48% | -$838K | 0.54% | 60 |
|
|
2016
Q2 | $1.74M | Sell |
52,122
-6,008
| -10% | -$192K | 1.07% | 30 |
|
|
2016
Q1 | $1.64M | Sell |
58,130
-97,056
| -63% | -$2.77M | 1.11% | 26 |
|
|
2015
Q4 | $4.75M | Buy |
155,186
+115,782
| +294% | +$3.64M | 2.85% | 3 |
|
|
2015
Q3 | $1.17M | Sell |
39,404
-44,658
| -53% | -$1.43M | 0.8% | 41 |
|
|
2015
Q2 | $2.67M | Sell |
84,062
-48,410
| -37% | -$1.58M | 1.2% | 26 |
|
|
2015
Q1 | $4.37M | Buy |
132,472
+87,271
| +193% | +$2.77M | 1.89% | 13 |
|
|
2014
Q4 | $1.34M | Buy |
45,201
+169
| +0.4% | +$4.85K | 0.59% | 53 |
|
|
2014
Q3 | $1.26M | Sell |
45,032
-316
| -0.7% | -$8.87K | 0.61% | 51 |
|
|
2014
Q2 | $1.28M | Sell |
45,348
-22,556
| -33% | -$643K | 0.53% | 54 |
|
|
2014
Q1 | $2.07M | Sell |
67,904
-3,162
| -4% | -$94.3K | 0.96% | 38 |
|
|
2013
Q4 | $2.06M | Sell |
71,066
-8,116
| -10% | -$236K | 0.88% | 40 |
|
|
2013
Q3 | $2.16M | Buy |
79,182
+1,265
| +2% | +$34.4K | 1.11% | 31 |
|
|
2013
Q2 | $2.07M | Buy |
+77,917
| New | +$2.15M | 1.22% | 27 |
|
Other funds holding PFE
Eidelman Virant Capital's PFE Position: Q1 2022 in Review
Eidelman Virant Capital sold out of Pfizer (PFE) in Q1 2022, closing a stake of 3,675 shares — an estimated $218K sold.
Eidelman Virant Capital first reported a position in PFE in Q2 2013 and held it in 34 quarters. The position peaked at $5.21M in Q3 2017. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Eidelman Virant Capital reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
- Eidelman Virant Capital sold 3,675 Pfizer shares in Q1 2022, an estimated $218K.
- Eidelman Virant Capital first reported a position in Pfizer in Q2 2013 and held it in 34 quarters.
- Eidelman Virant Capital's Pfizer position peaked at $5.21M in Q3 2017.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Eidelman Virant Capital's 13F filing for Q1 2022, filed 12 Apr 2022.